Overview: Influenza B RNA TestIntroduction: The Influenza B RNA Test detects Influenza B RNA to confirm active infection, helping diagnose and guide treatment for flu symptoms like fever or cough. Affecting 1 in 15 people annually, Influenza B poses diagnostic challenges due to seasonal variation. Following 2023 Centers for Disease Control and Prevention (CDC) guidelines, it uses RT-PCR for high sensitivity, supporting virology screening. This test is essential for diagnosis, treatment planning, and improving outcomes in infectious disease.
Other Names: Influenza B RNA Test, Active Flu B Assay.
FDA Status: FDA-approved test, meeting virology standards for diagnostic reliability.
Historical Milestone: Influenza RNA testing began in the 1990s with research by Fouchier, who developed RT-PCR methods. RT-PCR advancements in the 2000s by Roche improved detection, surpassing earlier culture methods.
Purpose: Detects Influenza B RNA to confirm active infection, guides antiviral therapy, and evaluates patients with flu symptoms, aiming to reduce severity.
Test Parameters: Influenza B RNA presence
Pretest Condition: Fresh nasopharyngeal swab required. Collect swab or sputum. Report history of flu symptoms.
Specimen: Nasopharyngeal Swab (sterile swab/transport medium, 1-2 swabs), Sputum (sterile container, 5-10 mL); Nasopharyngeal swab in sterile container. Transport in a biohazard container.
Sample Stability at Room Temperature: 4 hours
Sample Stability at Refrigeration: 24 hours
Sample Stability at Frozen: Not recommended
Medical History: Document fever, cough, or body aches. Include current medications or vaccination status.
Consent: Written consent required, detailing the test's purpose, flu risks (e.g., pneumonia), and sample collection risks.
Procedural Considerations: Uses RT-PCR to detect RNA, requiring labs with thermal cyclers. Results available in 1-2 days. Performed in labs with strict handling.
Factors Affecting Result Accuracy: Sample delay or contamination can affect results. Medications may not affect results but require correlation.
Clinical Significance: Positive RNA confirms active infection, guiding therapy. Early treatment might reduce severity, while untreated cases lead to complications. Negative results may require repeat testing.
Specialist Consultation: Consult an infectious disease specialist for interpretation.
Additional Supporting Tests: Influenza B IgM, chest X-ray, or viral culture to confirm diagnosis.
Test Limitations: Specific to active infection; correlation with symptoms needed. False negatives possible with low viral load.
References: CDC Guidelines, 2023; Journal of Virology, Fouchier RA, 2022.
